Floatz logo

cpl500036 - high dose

Dyskinesia, Medication-Induced

Celon Pharma SAPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Dyskinesia, Medication-Induced cohort.

Asset / SponsorPhaseRating
LEVODOPA
Sumitomo Pharma Co., Ltd.
Phase 4A
carbidopa
AbbVie (prior sponsor, Abbott)
Phase 4BBB
Emd 128130
EMD Serono
Phase 3BBB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BBB
Amantadine
Adamas Pharmaceuticals, Inc.
Phase 3BBB

View all 29 →

Same molecule, other indications

cpl500036 - high dose is also rated in:

schizophreniaDormant
CCC
Indicative ·
51 / 100
View asset →
Parkinson diseaseDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →